Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio for Target Lesion Revascularization in Patients With Drug-Eluting Stent Implantation

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2025 Mar 12

PMID 40070681

Authors

He Meng

Xiujun Zhou

Lushan Li

Yuanying Liu

Yujie Liu

Ying Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Severe in-stent restenosis (ISR) following the implantation of drug-eluting stent (DES) can lead to recurrent angina pectoris or even acute myocardial infarction, thereby necessitating target lesion revascularization (TLR). Prior studies have confirmed the correlation between the monocyte to high-density lipoprotein cholesterol ratio (MHR) and ISR after DES implantation. The potential of MHR to predict TLR following DES implantation remains an area of ongoing research and may have significant clinical implications.

Methods: A retrospective analysis was conducted on a consecutive series of 474 patients undergoing DES implantation and follow-up coronary angiography between December 1, 2014 and December 1, 2022. The patients were categorized into two distinct groups according to their exposure to TLR. To assess the predictive performance of the MHR with respect to TLR, we utilized multivariate logistic regression analysis and receiver operating characteristic (ROC) curve analysis.

Results: The study revealed a significant elevation in the MHR value within the TLR group compared to the non-TLR group (12.34 vs 8.97; P < 0.001). MHR was identified as an independent predictor of TLR (Odds Ratio [OR] = 1.162; 95% Confidence Interval [CI]: 1.102-1.225). The area under the curve (AUC) was found to be 0.712 (95% CI: 0.664-0.759). When the MHR exceeded 10.98, the specificity for predicting TLR was 75.8%, and the sensitivity was 58.0%. When the MHR was incorporated into the predictive model comprising established risk factors, there was a notable improvement in the AUC, from 0.689 to 0.749 (P < 0.001). Additionally, there was a significant categorical net reclassification improvement (NRI) of 0.183 (P < 0.001) and an integrated discrimination improvement (IDI) of 0.074 (P < 0.001).

Conclusion: The MHR functions as a predictor for TLR subsequent to DES implantation. Incorporating MHR into the predictive model improves the model's accuracy, indicating its potential value for clinical application.

References

Nagano Y, Otake H, Toba T, Kuroda K, Shinkura Y, Tahara N . Impaired Cholesterol-Uptake Capacity of HDL Might Promote Target-Lesion Revascularization by Inducing Neoatherosclerosis After Stent Implantation. J Am Heart Assoc. 2019; 8(9):e011975. PMC: 6512103. DOI: 10.1161/JAHA.119.011975. View

Alfonso F, Byrne R, Rivero F, Kastrati A . Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014; 63(24):2659-73. DOI: 10.1016/j.jacc.2014.02.545. View

Zeiher A, Schachinger V . Coronary endothelial vasodilator dysfunction: clinical relevance and therapeutic implications. Z Kardiol. 1994; 83 Suppl 4:7-14. View

Murphy A, Woollard K, Hoang A, Mukhamedova N, Stirzaker R, McCormick S . High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008; 28(11):2071-7. DOI: 10.1161/ATVBAHA.108.168690. View

Neumann F, Sousa-Uva M, Ahlsson A, Alfonso F, Banning A, Benedetto U . 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018; 40(2):87-165. DOI: 10.1093/eurheartj/ehy394. View

Yilmaz S, Akboga M, Sen F, Balci K, Aras D, Temizhan A . Usefulness of the monocyte-to-high-density lipoprotein cholesterol ratio to predict bare metal stent restenosis. Biomark Med. 2016; 10(9):959-66. DOI: 10.2217/bmm-2016-0069. View

Akboga M, Balci K, Maden O, Goktug Ertem A, Kirbas O, Yayla C . Usefulness of monocyte to HDL-cholesterol ratio to predict high SYNTAX score in patients with stable coronary artery disease. Biomark Med. 2016; 10(4):375-83. DOI: 10.2217/bmm-2015-0050. View

Serruys P, Kutryk M, Ong A . Coronary-artery stents. N Engl J Med. 2006; 354(5):483-95. DOI: 10.1056/NEJMra051091. View

Barter P, Nicholls S, Rye K, Anantharamaiah G, Navab M, Fogelman A . Antiinflammatory properties of HDL. Circ Res. 2004; 95(8):764-72. DOI: 10.1161/01.RES.0000146094.59640.13. View

Liu Y, Imanishi T, Ikejima H, Tsujioka H, Ozaki Y, Kuroi A . Association between circulating monocyte subsets and in-stent restenosis after coronary stent implantation in patients with ST-elevation myocardial infarction. Circ J. 2010; 74(12):2585-91. DOI: 10.1253/circj.cj-10-0544. View

10.

Garcia-Garcia H, McFadden E, Farb A, Mehran R, Stone G, Spertus J . Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Eur Heart J. 2018; 39(23):2192-2207. DOI: 10.1093/eurheartj/ehy223. View

11.

Grewe P, Deneke T, Machraoui A, Barmeyer J, Muller K . Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol. 2000; 35(1):157-63. DOI: 10.1016/s0735-1097(99)00486-6. View

12.

Zhan X, Pan D, Wei X, Wen D, Yan C, Xiao J . Monocyte to high-density lipoprotein ratio and cardiovascular events in patients on peritoneal dialysis. Nutr Metab Cardiovasc Dis. 2020; 30(7):1130-1136. DOI: 10.1016/j.numecd.2020.03.011. View

13.

Kandzari D, Koolen J, Doros G, Garcia-Garcia H, Bennett J, Roguin A . Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial. JACC Cardiovasc Interv. 2020; 13(11):1343-1353. DOI: 10.1016/j.jcin.2020.02.019. View

14.

Fukuda D, Shimada K, Tanaka A, Kawarabayashi T, Yoshiyama M, Yoshikawa J . Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol. 2004; 43(1):18-23. DOI: 10.1016/j.jacc.2003.08.026. View

15.

Neumann F, Sousa-Uva M . 'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization. Eur Heart J. 2019; 40(2):79-80. DOI: 10.1093/eurheartj/ehy855. View

16.

Hoffmann R, Mintz G, Dussaillant G, Popma J, Pichard A, Satler L . Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996; 94(6):1247-54. DOI: 10.1161/01.cir.94.6.1247. View

17.

Dangas G, Claessen B, Caixeta A, Sanidas E, Mintz G, Mehran R . In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010; 56(23):1897-907. DOI: 10.1016/j.jacc.2010.07.028. View

18.

Seetharam D, Mineo C, Gormley A, Gibson L, Vongpatanasin W, Chambliss K . High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2005; 98(1):63-72. DOI: 10.1161/01.RES.0000199272.59432.5b. View

19.

Ucar F . A potential marker of bare metal stent restenosis: monocyte count - to- HDL cholesterol ratio. BMC Cardiovasc Disord. 2016; 16(1):186. PMC: 5048646. DOI: 10.1186/s12872-016-0367-3. View